CINECA IRIS Institutional Research Information System

ELISEI, ROSSELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 37.430
AS - Asia 19.214
EU - Europa 17.540
SA - Sud America 3.053
AF - Africa 940
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 19
Totale 78.228
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 36.447
SG - Singapore 5.962
CN - Cina 5.269
IT - Italia 4.684
DE - Germania 3.788
HK - Hong Kong 3.212
SE - Svezia 2.870
BR - Brasile 2.512
VN - Vietnam 1.682
GB - Regno Unito 1.198
BG - Bulgaria 1.151
TR - Turchia 754
FR - Francia 720
CA - Canada 715
RU - Federazione Russa 642
FI - Finlandia 611
AT - Austria 537
IN - India 493
UA - Ucraina 416
CI - Costa d'Avorio 391
KR - Corea 372
JP - Giappone 360
BD - Bangladesh 209
SN - Senegal 192
NL - Olanda 190
AR - Argentina 180
CH - Svizzera 150
IQ - Iraq 145
MX - Messico 133
PL - Polonia 107
PK - Pakistan 104
BE - Belgio 93
ZA - Sudafrica 93
ID - Indonesia 92
MA - Marocco 91
SA - Arabia Saudita 90
EC - Ecuador 83
ES - Italia 73
VE - Venezuela 67
CO - Colombia 64
UZ - Uzbekistan 60
EE - Estonia 50
CZ - Repubblica Ceca 48
PH - Filippine 44
CL - Cile 42
IR - Iran 38
JO - Giordania 33
KE - Kenya 33
LT - Lituania 33
UY - Uruguay 33
GR - Grecia 31
AZ - Azerbaigian 30
IE - Irlanda 30
PY - Paraguay 30
MY - Malesia 28
NP - Nepal 27
AE - Emirati Arabi Uniti 26
AU - Australia 26
EG - Egitto 24
PE - Perù 24
IL - Israele 23
JM - Giamaica 23
TN - Tunisia 23
DZ - Algeria 22
TW - Taiwan 21
PA - Panama 20
HU - Ungheria 19
OM - Oman 18
RO - Romania 17
PS - Palestinian Territory 16
RS - Serbia 16
CR - Costa Rica 15
KZ - Kazakistan 15
LB - Libano 15
NG - Nigeria 15
KG - Kirghizistan 14
BO - Bolivia 13
EU - Europa 13
DO - Repubblica Dominicana 12
ET - Etiopia 11
HN - Honduras 11
PT - Portogallo 11
TH - Thailandia 11
TT - Trinidad e Tobago 11
SK - Slovacchia (Repubblica Slovacca) 10
AL - Albania 9
BJ - Benin 9
BH - Bahrain 8
BY - Bielorussia 8
SY - Repubblica araba siriana 8
GT - Guatemala 7
SV - El Salvador 7
CY - Cipro 6
DK - Danimarca 6
GA - Gabon 6
GE - Georgia 6
BZ - Belize 5
MG - Madagascar 5
NZ - Nuova Zelanda 5
XK - ???statistics.table.value.countryCode.XK??? 5
Totale 78.127
Salva come PNG Salva come JPEG
Città #
Ashburn 4.067
Singapore 3.324
Hong Kong 3.154
Woodbridge 2.865
Dallas 2.844
Fairfield 2.810
Chandler 2.114
San Jose 2.111
Ann Arbor 1.965
Houston 1.905
Santa Clara 1.780
Seattle 1.228
Sofia 1.143
Shanghai 1.131
Beijing 1.049
Milan 1.047
Wilmington 1.037
Cambridge 967
New York 920
Los Angeles 605
Boardman 583
Ottawa 523
Princeton 520
Vienna 479
Hefei 445
Lawrence 442
Ho Chi Minh City 441
Jacksonville 438
Lauterbourg 425
Munich 395
Abidjan 391
Medford 367
Izmir 353
Seoul 345
Serra 333
Tokyo 315
Hanoi 302
London 295
Des Moines 280
Nanjing 268
Frankfurt am Main 256
Pisa 253
Florence 249
Istanbul 239
Rome 239
São Paulo 221
Redondo Beach 194
Council Bluffs 193
Dakar 192
Buffalo 191
Dearborn 190
Helsinki 190
Dong Ket 187
San Diego 169
Boulder 133
Bern 120
Bremen 117
Orem 116
Düsseldorf 109
Turku 108
Redwood City 107
Columbus 101
Nanchang 100
Chicago 98
Ogden 90
Brussels 86
Fuzhou 86
Tianjin 81
Rio de Janeiro 78
Washington 78
The Dalles 76
Kunming 75
Jüchen 74
Belo Horizonte 73
Changsha 69
Nuremberg 69
Phoenix 67
Baghdad 65
Atlanta 63
Amsterdam 61
Montreal 59
Warsaw 59
Denver 58
Lancaster 58
Naples 57
Shenyang 57
Brooklyn 56
Guangzhou 55
Haiphong 55
Kocaeli 54
Tashkent 54
Hebei 53
Chennai 52
Nürnberg 52
Quanzhou 51
Toronto 51
Da Nang 50
Jiaxing 50
Redmond 49
Norwalk 48
Totale 52.347
Salva come PNG Salva come JPEG
Nome #
I CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE HANNO ORIGINE GENETICA INDIPENDENTE 1.154
L’ANALISI GENETICA DI CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE RIVELA LA LORO NATURA CASUALE 340
Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy 318
Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma 312
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 288
LOW PREVALENCE OF THE SOMATIC M918T RET MUTATION IN MICRO-MEDULLARY THYROID CANCER. 273
T cell responses to orbital antigens in thyroid-associated ophthalmopathy. 269
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10 years follow up study 264
null 259
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 257
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. 253
Risk of Differentiated Thyroid Carcinoma and Polymorphisms within the Susceptibility Cancer Region 8q24 253
Thyroid carcinoma in thyrotoxic patients treated by surgery. 252
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 252
Low-Risk Differentiated Thyroid Cancer with BRAFV600E mutation is more difficult to cure than negative cases: a 5-year follow-up study. 250
Identification of two distinct molecular subtypes by digital RNA counting of "non-invasive follicular tumour with papillary-like nuclear features (NIFTP)" 249
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 248
Advances in the follow-up of differentiated or medullary thyroid cancer. 248
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 242
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 242
Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma 241
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 240
A comprehensive meta-analysis of case-control association studies to evaluate polymorphisms associated with the risk of differentiated thyroid carcinoma 240
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 239
Circulating neuron-specific enolase in medullary thyroid cancer. 238
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 238
Studies with recombinant autoepitopes of thyroid peroxidase: evidence suggesting an epitope shared between the thyroid and the gastric parietal cell. 234
Lenvatinib Administered via Nasogastric Tube in Poorly Differentiated Thyroid Cancer 234
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 233
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 232
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 231
Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients 230
A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure 228
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma 227
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 226
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 226
Targeted Therapy in Thyroid Cancer: State of the Art 223
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 221
Incidental versus clinically evident thyroid cancer: A 5-year follow-up study 220
Management of thyrotoxicosis induced by PD1 or PD-L1 blockade 220
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 219
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 219
Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients 217
Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland 216
Inherited variants in genes somatically mutated in thyroid cancer 216
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 216
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes 215
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 214
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 213
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 212
Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer 211
Thyroid autoimmunity, thyroglobulin autoantibodies and thyroid cancer prognosis 210
Strategies for single base gene editing in an immortalized human cell line by CRISPR/Cas9 technology 208
Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. 208
Thyroid cancer in children and adolescents. 208
Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. 208
RET point mutations in Thyroid Carcinoma 208
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 207
mRNA and miRNA expression profiling of follicular variant of papillary thyroid carcinoma with and without distant metastases 206
RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors 205
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium 205
Advances in the follow-up of differentiated or medullary thyroid cancer 205
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 205
Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. 204
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study 204
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 204
Multiple Endocrine Neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes 203
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 202
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 202
Polymorphisms within the RET proto-oncogene and risk of sporadic medullary thyroid carcinoma 202
Molecular biology studies on mesothelioma tumor samples: preliminary data on H-ras, p21, and SV40. 200
Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma 199
Serum bone Gla-protein (osteocalcin) in patients with bone metastases from thyroid cancer 197
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal 196
TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations. 196
mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study 196
The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy 196
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 196
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 195
Cytological and Ultrasound Features of Thyroid Nodules Correlate with Histotypes and Variants of Thyroid Carcinoma 194
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas 194
Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. 194
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 194
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. 193
Lack of evidence supporting the presence of mRNA for the thyrotropin receptor in extra-ocular muscle. 192
Genome-wide association study on differentiated thyroid cancer. 192
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 192
Muscle autoantigens in thyroid associated ophthalmopathy: the limits of molecular genetics. 191
Prevalence of papillary thyroid cancer (PTC) in patients affected by medullary thyroid cancer (MTC) 191
Routine serum calcitonin measurement in the evaluation of thyroid nodules 190
Il carcinoma tiroideo: nuove prospettive terapeutiche. 190
DIAGNOSTIC AND THERAPEUTIC ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 190
Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk. 189
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer 189
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 189
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 188
A patient with MEN1 and end‑stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation 187
Role Of Prophylactic Central Compartment Lymph Node Dissection On The Outcome Of Patients With Papillary Thyroid Carcinoma And Synchronous Ipsilateral Cervical Lymph Node Metastases 187
Pre- And Post-Operative Circulating Tumoral Dna In Patients With Medullary Thyroid Carcinoma 187
Simian virus 40-like sequences from early and late regions in human thyroid tumors of different histotypes 186
Totale 22.886
Salva come PNG Salva come JPEG
Categoria #
all - tutte 220.334
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 220.334
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021801 0 0 0 0 0 0 0 0 0 0 241 560
2021/20225.311 124 233 126 379 1.096 695 176 241 284 218 338 1.401
2022/20237.655 966 1.118 608 608 764 905 136 612 1.319 73 454 92
2023/20245.327 584 553 635 380 710 922 286 172 141 115 261 568
2024/202516.730 169 656 232 984 1.584 1.498 1.322 920 1.781 2.166 1.842 3.576
2025/202619.979 1.479 2.981 2.542 2.078 1.952 1.677 2.998 921 1.125 1.802 424 0
Totale 79.275